Table 1. Patient characteristics and immunotherapy.
| Age(years) | Sex | Smoking | Cancer | Gene* | PD-L1 | TNM Stage | PS | Previous therapies | Time since TB diagnosis to initiation of ICIs (years) | ICIs | Line | Overall duration (months)# | PFS (months)# | irAEs | Treatment of irAEs | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | 62 | M | Never | LUSC | WT | NA | IV | 2 | None | 0.7 | Pembrolizumab | 1 | 2.1 | 2.1 | Renal dysfunction, III° | Discontinuation of ICI + corticosteroids |
| P2 | 68 | M | Never | LUSC | WT | NA | Recurrent | 1 | None | 12.3 | Pembrolizumab | 1 | 9.9 | 5.6 | None | None |
| P3 | 68 | M | Never | LUAD | 20ins | 30% | Recurrent | 1 | None | 0.2 | Pembrolizumab | 1 | 2.2 | 2.2 | Liver dysfunction, I° | Monitor liver function |
| P4 | 61 | M | Smoker | LUSC | NA | 0 | IV | 1 | TC (8 cycles) | 12.2 | Camrelizumab | 2 | 3.8 | 3.8 | None | None |
| P5 | 66 | M | Smoker | LUAD | WT | NA | IV | 1 | None | 5.7 | Camrelizumab | 1 | 7.0 | 5.6 | None | None |
| P6 | 79 | M | Never | LUSC | WT | 80% | Recurrent | 1 | None | 53.4 | Toripalimab | 1 | 1.8+ | 1.8+ | None | None |
| P7 | 42 | F | Never | LUAD | 19del | 40% | IIIb | 1 | 1st line: afatinib (1 month) 2nd line: AC (4 cycles) | 7.4 | Toripalimab | 3 | 2.1 | 2.1 | None | None |
| P8 | 68 | M | Smoker | LUSC | NA | 0 | IV | 1 | None | 27.8 | Pembrolizumab | 1 | 5.6+ | 5.6+ | Exfoliative dermatitis, III° | Discontinuation of ICI + corticosteroids |
| P9 | 59 | M | Smoker | LUSC | NA | 30% | Recurrent | 1 | None | 10.2 | Pembrolizumab | 1 | 1.3 | 1.3 | None | None |
| P10 | 52 | M | Smoker | LUAD | WT | 0 | IIIc | 1 | GP (4 cycles) | 27.2 | Tislelizumab | 2 | 5.5 | 5.5 | None | None |
| P11 | 45 | F | Never | LUAD | WT | 30% | IV | 1 | None | 5.8 | Pembrolizumab | 1 | 3.6 | 3.6 | None | None |
| P12 | 67 | M | Smoker | LUSC | WT | 0 | IIIb | 1 | 1st line: NP (4 cycles) 2nd line: docetaxel (2 cycles) | 5.2 | Camrelizumab | 3 | 12.5 | 12.5 | None | None |
| P13 | 43 | M | Never | LUSC | NA | 5% | Recurrent | 1 | GP (6 cycles) | 4.1 | Pembrolizumab | 2 | 15.3 | 14.4 | None | None |
Gene*: Driver oncogene alteration. #, numbers followed by ‘+’: patients who were still responding to immunotherapy at the censor date (March 1, 2021) or who were lost to follow-up were censored at the last date of follow-up. PS, Eastern Cooperative Oncology Group performance status; TB, tuberculosis; ICIs, immune checkpoint inhibitors; PFS, progression-free survival; irAEs, immune-related adverse effects; M, male; F, female; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; WT, wild type; NA, not available; TC, paclitaxel + carboplatin; AC, pemetrexed + carboplatin; GP, gemcitabine + cisplatin; NP, vinorelbine + cisplatin.